TVTX — Travere Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1438533 ·
Last close
$59.44
Market Cap
$5.60B
52W High
$68.73
52W Low
$22.06
ADV30
1,436,600
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 169,584,000 160,349,000 3,954,000 -34,797,000 799,360,000 117,735,000 774,838,000
Mar 2026 127,199,000 100,433,000 -36,915,000 -37,102,000 555,188,000 78,362,000 456,460,000
Dec 2025 129,689,000 127,136,000 -32,428,000 2,729,000 605,191,000 93,035,000 490,363,000
Sep 2025 164,859,000 163,274,000 24,931,000 25,706,000 538,581,000 110,930,000 465,017,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$92,700,000
Investing CF
$-202,986,000
Financing CF
$153,061,000
CapEx
$-77,536,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.46
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,544,612,000
Inventory
$7,835,000
Receivables
$80,636,000
ST Investments
$371,442,000
EBIT TTM
$-57,593,000
Pretax Income TTM
$-67,074,000
Interest Exp TTM
$9,481,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$591,329,984
EBITDA
$22,913,000
Free Cash Flow
$-18,254,250
Enterprise Value
$6,364,983,808
Total Cash
$489,176,992
Total Debt
$616,905,024
Shares Out
94,261,082
Trailing EPS
$-0.73
Book Value
$1.07
ROE
-236.4%
ROA
-3.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 490,728,000 -62,824,000 -25,546,000 605,191,000 490,363,000 114,828,000 37,784,000
Dec 2024 233,175,000 -321,389,000 -321,545,000 594,125,000 535,048,000 59,077,000 -237,475,000
Dec 2023 145,238,000 -376,744,000 -111,399,000 788,913,000 588,103,000 200,810,000 -280,021,000
Dec 2022 109,460,000 -319,813,000 -278,482,000 672,585,000 629,734,000 42,851,000 -186,291,000

TTM Snapshot

Revenues TTM
$209,800,000
NetIncome TTM
$-14,958,000
OpCashFlow TTM
$0
Assets (Latest)
$605,191,000
Forward EPS
$5.67

Max Pain — expiry 2027-01-15

max pain strike: $30.00 · spot: $59.44 · call oi: 14,336 · put oi: 2,555
Expected Move to 2027-01-15: ±$11.40 (19.18%) — implied range $48.04 – $70.84 · ATM straddle on $60.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
COGT Cogent Biosciences, Inc. $5.61B $32.31 —
ORKA Oruka Therapeutics, Inc. $5.59B $84.46 —
MIRM Mirum Pharmaceuticals, Inc. $5.82B $89.70 —
PTCT PTC THERAPEUTICS, INC. $5.23B $62.67 —
LGND LIGAND PHARMACEUTICALS INC $6.01B $301.52 —

News headlines (Yahoo Finance, 1h cache)

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G
2026-09-23 11:00 · Yahoo
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
2026-09-23 01:13 · Yahoo
Travere Therapeutics Announces Planned Chief Executive Officer Transition
2026-09-21 20:05 · Yahoo
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-17 20:30 · Yahoo
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-11 21:00 · Yahoo
Travere Therapeutics' Outlook Brightens As Turnaround Looms
2026-09-08 19:44 · Yahoo
IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'
2026-08-21 17:09 · Yahoo
Three Biotech Stocks Stick Out With Their Stellar Charts
2026-08-21 16:09 · Yahoo
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
2026-08-18 10:01 · Yahoo
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript
2026-08-12 00:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.